

**Medication Adherence and Treatment Satisfaction in
Chronic Obstructive Pulmonary Disease and Bronchial Asthma**

Thesis

Submitted for Partial Fulfillment of Master
Degree in Chest Diseases and Tuberculosis

By

Yosra Elemary Afifi Mohran

M.B, B.CH.

Under Supervision of

Professor: Yasser Mustafa Mohammed

Professor of Chest Diseases

Faculty of Medicine –Ain Shams University

Assistant Professor: Iman Hassan Galal

Assistant Professor of Chest Diseases

Faculty of Medicine –Ain Shams University

**Faculty of Medicine
Ain Shams University
2013**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَاللَّهُمَّ صَلِّ وَسَلِّمْ عَلَى نَبِيِّهِ مُحَمَّدٍ وَعَلَى آلِهِ وَوَجِّعْ لَهُمُ الْبُحْرَانِ

وَالْعِلْمِ وَالْحِكْمَةِ وَالْجَنَّةِ وَالْجَنَّةِ وَالْجَنَّةِ وَالْجَنَّةِ

Acknowledgement

Thanks first and last to Allah as we owe him for his great care, support and guidance in every step in our life.

I would like to express my cordial appreciation and infinite gratitude to, *Prof. Yasser Mustafa Mohammed* Professor of Chest Diseases, Faculty of Medicine, Ain Shams University for his infinite support, valuable advice and guidance.

I would like to express my deep thanks and gratitude to *Dr. Iman Hassan Galal*, Assistant Professor of Chest diseases, Faculty of Medicine, Ain Shams University for his constant support which has been of greatest value in accomplishing this work.

Lastly, I would like to express my deep thanks to every person assisted me to complete this research.

List of Contents

	Page
Introduction -----	1
Aim of the work -----	2
Review of literature -----	3
Chronic obstructive pulmonary disease (COPD)	3
Bronchial asthma	20
<i>Medication Adherence and Treatment satisfaction</i>	33
Subjects & Methods-----	43
Results-----	61
Discussion -----	140
Summary -----	146
Recommendations-----	151
References-----	152
Arabic summary -----	161

List of Abbreviations

ACCP: American College of Clinical Pharmacy

ACP: American College of Physicians

ACQ5: Asthma Control Questionnaire

ACT: Asthma Control Test

IgE: Immunoglobulin E

Anti –IL–4: Interleukin4

Anti –IL– 5: Interleukin5

Anti –IL–8 : Interleukin8

Anti –IL-13 : Interleukin13

Anti- LTB4: Anti-Leukotriene B4

ATS: American Thoracic Society

BMI: Body Mass Index

COPD: Chronic Obstructive Pulmonary Disease

CS: Corticosteroid

CXCR2: Chemokine (C–X–C Motif) Receptor 2

ERS: European Respiratory Society

ECG: Echocardiography

FEV1: Forced Expiratory Volume 1

FEV6: Forced Expiratory Volume 6

FEV₁/FVC : Forced expiratory volume in first second/ forced vital capacity

FVC: Forced Vital Capacity

GINA: Global Initiative for Asthma

GOLD: Global Initiative for Chronic Obstructive Lung Disease

HIV: Human Immunodeficiency Virus

ICs: Inhaled Corticosteroid

ICU: Intensive Care Unite

LABA: Long Acting Beta–2 Agonists

LABD: Long Acting Bronchodilator

MRC; Medical Research Council

NAEPP: National Asthma Education and Prevention Program

NIV: Noninvasive Mechanical Ventilation

PaCO₂; Arterial partial Pressure of Carbon Dioxide

PaO₂: Arterial partial Pressure of Oxygen

PEF: Peak Expiratory Flow Rate

PKa: Dissociation Constant

SABA: Short Acting Beta–2 Agonists

SaO₂: Oxygen Saturation

TH1: The T helper cell1

TSQM: Treatment Satisfaction Questionnaire for Medication

WHO: World Health Organization

\$: Dollar

List of Tables

Table 1: The BODE index is a composite marker of disease taking into consideration the systemic nature of COPD. 13

Table 2: Main chronic obstructive pulmonary disease comorbidities 14

Table 3: Differential Diagnoses of COPD. 15

Table 4: Factors affecting adherence to asthma treatment and interventions for improving it, listed according to the five dimensions and the interventions used to improve adherence 38

Table 5: Descriptive-demographic statistics of all included patients 61

Table 6 Pulmonary function test among all studied patients 62

Table 7: Descriptive-demographic statistics of asthma group 63

Table 8 Pulmonary function test among asthma group 64

Table 9: Descriptive statistic of Morisky medication adherence scale among asthma group 65

Table 10: Descriptive statistic of Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 among asthma group 67

Table 11: Descriptive-demographic statistics of COPD group 71

Table 12 Pulmonary function test among COPD group 72

Table 13: Descriptive statistic of Morisky medication adherence scale among COPD group 73

Table 14: Descriptive statistic of Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 among COPD group 75

Table (15) Comparison between COPD and Asthma patients regarding demographic characteristics 79

Table (16): Comparison between COPD and Asthma groups regarding pulmonary functions 84

Table (17): Comparison between COPD and asthma groups regarding TSQM 86

Table (18): Comparison between COPD and Asthma groups regarding Morisky medication adherence items(MMAS) 89

Table (19): Correlation between scales and other factors (COPD) group 91

Table (20): Correlation between scales and other factors (Asthma group) 106

Table (21): Comparison between males and females regarding scales 129

Table (22): Comparison between smokers and smokers regarding scales.130

Table (23): Comparison between recurrent and non-recurrent hospital admission regarding scales 131

Table (24): Comparison between co morbid and non-comorbid regarding scales 132

Table (25): Comparison between subjective treatment regularity and irregularity regarding scales 133

Table (26): Comparison between subjective treatment satisfaction and dissatisfaction regarding scales 134

Table (27): Regression analysis for factors affecting MMAS scale 135

Table (28): Regression analysis for factors affecting TSQM global satisfaction subscale 136

Table (29): Regression analysis for factors affecting TSQM convenience subscale 137

Table (30): Regression analysis for factors affecting TSQM side effects subscale 136

Table (31): Regression analysis for factors affecting TSQM effectiveness subscale 139

List of figures

Figure (1): Micro lab spirometer 57

Figure (2): Comparison between COPD and bronchial asthma patients regarding cigarette smokers, recurrent hospital admission, co morbidities, & current treatment, and normal X-ray findings. 81

Figure (3) Comparison between COPD and bronchial asthma patients regarding sex and level of education. 81

Figure (4) Comparison between COPD and bronchial asthma patients regarding residents 82

Figure (5): Comparison between COPD and asthma patients regarding smoking 82

Figure (6): Comparison between COPD and Asthma groups regarding subjective satisfaction 83

Figure (7): Comparison between COPD and Asthma patients regarding pulmonary functions 85

Figure (8): Comparison between COPD and asthma patients regarding bronchodilator reversibility test 85

Figure (9): Comparison between COPD and Asthma groups regarding TSQM subscales 88

Figure (10): Comparison between COPD and Asthma groups regarding MMAS 90

Figure (11): Correlation between TSQM-global satisfaction and duration of general chest medications (COPD group) 92

Figure (12): Correlation between TSQM-effectiveness and TSQM-side effects (COPD group) 92

Figure (13): Correlation between TSQM-effectiveness and TSQM-convenience (COPD group) 93

Figure (14): Correlation between TSQM-effectiveness and TSQM-global satisfaction (COPD group) 93

Figure (15): Correlation between TSQM-effectiveness and general medication Duration (COPD group) 94

Figure (16): Correlation between TSQM-effectiveness and FVC (COPD group) 94

Figure (17): Correlation between TSQM-effectiveness and FVC% predicted (COPD group) 95

Figure (18): Correlation between TSQM-effectiveness and FEV_1 (COPD group) 96

Figure (19): Correlation between TSQM-effectiveness and $FEV_1\%$ predicted (COPD group) 96

Figure (20): Correlation between TSQM-effectiveness and predicted FEF_{25-75} (COPD group) 97

Figure (21): Correlation between TSQM-side effects and TSQM global satisfaction (COPD group) 97

Figure (22): Correlation between TSQM-convenience and total MMAS(COPD group) 98

Figure (23): Correlation between TSQM-convenience and $FEV_1 / FVC\%$ (COPD group) 98

Figure (24): Correlation between TSQM-convenience and predicted FEF₂₅₋₇₅ (COPD group) 99

Figure (25): Correlation between TSQM-global satisfaction and general medication duration (COPD group) 99

Figure (26): Correlation between TSQM-global satisfaction and absolute FVC (COPD group) 100

Figure (27): Correlation between TSQM-global satisfaction and predicted FVC (COPD group) 100

Figure (28): Correlation between TSQM-global satisfaction and absolute FEV₁ (COPD group) 101

Figure (29): Correlation between TSQM-global satisfaction and predicted FEV₁ (COPD group) 101

Figure (30): Correlation between TSQM-global satisfaction and 102

Figure (31): Correlation between total MMAS and age (COPD group) 102

Figure (32): Correlation between total MMAS and general medication Duration (COPD group) 103

Figure (33): Correlation between total MMAS and absolute FVC (COPD group) 103

Figure (34): Correlation between total MMAS and absolutes FEV₁ (COPD group) 104

Figure (35): Correlation between total MMAS and duration of general chest medications predicted FEF₂₅₋₇₅ (COPD group) 107

Figure (36): Correlation between TSQM-effectiveness and TSQM-side effects (Asthmatic group) 108

Figure (37): Correlation between TSQM-effectiveness and TSQM-convenience (Asthmatic group) 108

Figure (38): Correlation between TSQM-effectiveness and TSQM-global satisfaction (Asthmatic group) 109

Figure (39): Correlation between TSQM-effectiveness and total MMAS(Asthmatic group) 109

Figure (40): Correlation between TSQM-effectiveness and FEV₁/FVC%(Asthmatic group) 110

Figure (41): Correlation between TSQM-effectiveness and absolute FVC (Asthmatic group) 110

Figure (42): Correlation between TSQM-effectiveness and predicted FVC (Asthmatic group) 111

Figure (43): Correlation between TSQM-effectiveness and absolute FEV₁(Asthmatic group) 111

Figure (44): Correlation between TSQM-effectiveness and predicted FEV₁(Asthma group) 112

Figure (45): Correlation between TSQM-effectiveness and predicted FEF₂₅₋₇₅(Asthmatic group) 112

Figure (46): Correlation between TSQM- side effects and TSQM-convenience (Asthmatic group) 113

Figure (47): Correlation between TSQM- side effects and TSQM-global satisfaction(Asthmatic group) 113

Figure (48): Correlation between TSQM- side effects and total MMAS(Asthmatic group) 114

Figure (49): Correlation between TSQM- side effects and absolute FVC(Asthmatic group) 114

Figure (50): Correlation between TSQM- side effects and predicted FVC (Asthmatic group) 115

Figure (51): Correlation between TSQM- side effects and absolute FEV₁(Asthmatic group) 115

Figure (52): Correlation between TSQM- side effects and predicted FEV₁(Asthmatic group) 116

Figure (53): Correlation between TSQM- side effects and predicted FEF₂₅₋₇₅(Asthmatic group) 116

Figure (54): Correlation between TSQM-convenience and TSQM-global satisfaction(Asthmatic group) 117

Figure (55): Correlation between TSQM- convenience and total MMAS(Asthmatic group) 117

Figure (56): Correlation between TSQM- convenience and FEV₁/FVC% (Asthmatic group) 118

Figure (57): Correlation between TSQM- convenience and absolute FVC (Asthmatic group) 118

Figure (58): Correlation between TSQM- convenience and predicted FVC (Asthmatic group) 119

Figure (59): Correlation between TSQM- convenience and absolute FEV₁(Asthmatic group) 119

Figure (60): Correlation between TSQM- convenience and predicted FEV₁ (Asthmatic group) 120

Figure (61): Correlation between TSQM- convenience and predicted FEF₂₅₋₇₅(Asthmatic group) 120

Figure (62): Correlation between TSQM- global satisfaction and total MMAS(Asthmatic group) 121

Figure (63): Correlation between TSQM- global satisfaction and FEV₁/FVC% (Asthmatic group) 121

Figure (64): Correlation between TSQM- global satisfaction and absolute FVC (Asthmatic group) 122

Figure (65): Correlation between TSQM- global satisfaction and predicted FVC (Asthmatic group) 122